Dr. Mai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1275 York Ave
New York, NY 10065
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2022 - 2025
- Johns Hopkins UniversityResidency, Internal Medicine, 2019 - 2022
- Johns Hopkins University School of MedicineClass of 2019
Certifications & Licensure
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsPredictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer.Nicholas Mai, Carlos H Dos Anjos, Pedram Razavi, Anton Safonov, Sujata Patil
NPJ Breast Cancer. 2024-10-18 - Pathologic complete response to KEYNOTE522 and HER2-directed therapy for synchronous TNBC and HER2+ breast cancer.Nicholas Mai, Jie-Fu Chen, Satshil Rana, Mark Robson, Sarat Chandarlapaty
NPJ Precision Oncology. 2024-07-28 - Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer.Nicholas Mai, Sara Myers, Sherry Shen, Stephanie Downs-Canner, Mark Robson
NPJ Breast Cancer. 2024-06-04
Journal Articles
- Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancerNicholas Mai et al, NPJ Breast, 2024
- Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast CancerNicholas Mai et al, NPJ Breast, 2024
- Pathologic complete response to KEYNOTE522 and HER2-directed therapy for synchronous TNBC and HER2+ breast cancerNicholas Mai etal, NPJ Precision Oncology, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: